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Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its   
therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen‐level dependent (BOLD) 
resting‐state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after 
treatment with psilocybin (serotonin agonist) for treatment‐resistant depression (TRD). Quality pre and post treatment fMRI data 
were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1‐week posttreatment 
and 47% met criteria for response at 5 weeks. Whole‐brain analyses revealed post‐treatment decreases in CBF in the temporal 
cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms. Focusing on a priori 
selected circuitry for RSFC analyses, increased RSFC was observed within the default‐mode network (DMN) post‐treatment. 
Increased ventromedial prefrontal cortex‐bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 
5‐weeks, as was decreased parahippocampal‐PFC RSFC. These data fill an important knowledge gap regarding the 
post‐treatment brain effects of psilocybin, and are the first in depressed patients. The post‐treatment brain changes are different 
to previously observed acute effects of psilocybin and other   
‘psychedelics’ yet were related to clinical outcomes. A ‘reset’ therapeutic mechanism is proposed.   
Psilocybin is the prodrug of psilocin (4-OH-dimethyltryptamine), a non-selective serotonin 2A receptor (5-HT2AR) agonist and classic 
‘psychedelic’ drug
1
. Both compounds occur naturally in the ‘psilocybe’ genus of mushrooms, and are structurally related to the endogenous 
neurotransmitter serotonin (5-OH-tryptamine, 5-HT). Psilocybin has an ancient and more recent history of medicinal-use. Administered in 
a supportive environment, with preparatory and integrative psychological care, it is used to facilitate emotional breakthrough and renewed 
perspective
2
. Accumulating evidence suggests that psilocybin with accompanying psychological support can be used safely to treat a range of 
psychiatric conditions
1
, including: end-of-life anxiety and depression
3–5
, alcohol and tobacco addiction
6,7
, obsessive compulsive disorder
8
, and 
most recently from our group, treatment-resistant major depression
9
. Findings from healthy volunteer studies
10
 and trials with other psyche-
delics
11–13
 supplement those from clinical studies showing that these drugs can have a rapid and lasting positive impact on mental health, 
often after just one or two doses. Such outcomes raise a number of important questions, including: what brain mechanisms mediate these 
effects?  
Most human functional neuroimaging studies of psychedelics have focused on their acute effects with the aim of elucidating the neural 
correlates of the ‘psychedelic state’
14,15
. Consistent with findings from animal research
16
, psychedelics appear to dysregulate cortical activity
14,17
, 
producing an ‘entropic’ brain state
18
, characterised by compromised modular but enhanced global connectivity - referred to previously as 
network ‘disintegration’ and ‘desegregation’
14
. These effects have been found to correlate with important aspects of the ‘psychedelic expe-
rience’, including ‘ego-dissolution’
14,17,19
, and were predictive of post-acute changes in the personality domain  
 ‘openness’
20
. To our knowledge, no studies have investigated >12 hour post-acute effects of psychedelics on human brain function 
(although see
12
), and few have looked at anatomical changes possibly related to psychedelic use
21,22
.  
The present study focused on changes in brain function before versus after psilocybin in patients with treatment-resistant depression 
who received two doses of the drug (10 mg followed by 25 mg, one-week apart) as part of an open-label clinical trial. Arterial spin labelling 
(ASL) and blood oxygen level dependent (BOLD) resting state functional connectivity (RSFC), were used to measure changes in cerebral 
blood flow (CBF) and functional connectivity before (baseline) and one-day after treatment with psilocybin (i.e. one day after the 25 mg 
dose). It has been suggested that the days subsequent to a psychedelic experience constitute a distinct phase, referred to as the ‘after-glow’, 
that is characterised by mood improvements and stress relief
23
. The rationale for scanning one-day post-treatment was to capture brain 
changes related to this so-called after-glow that might correlate with current mood improvements and/or longer-term prognoses. We 
predicted that resting-state CBF and FC would be altered post treatment and correlate with immediate and longer-term clinical 
improvements.  
With regards to ‘longer-term’ clinical outcomes, we chose to focus on a 5-week post-treatment endpoint due to a virtual 50:50 split 
between responders and non-responders at this time-point (QIDS-16) and that none of the patients went on to additional (and thus, 
confounding) treatments within this time frame. A select number of regions of interest were chosen a priori for CBF and RSFC analyses due 
to previous work implicating their involvement in depression and its treatment, e.g
24–26
.  
Results   
Nineteen patients with diagnoses of treatment resistant major depression completed pre-treatment and one-day post-treatment fMRI 
scanning. Excessive movement or other artefact meant that three patients were removed from the ASL analyses and four from the RSFC (SI 
Appendix), leaving sample sizes of 16 (mean age = 42.8 ±  
10.1 y, 4 females) and 15 (mean age = 42.8 ± 10.5 y, 4 females) for the ASL and BOLD analyses, respectively.  
Treatment with psilocybin produced rapid and sustained antidepressant effects. For the patients included in the ASL analysis (minus one 
patient whose scan 1 rating was not collected), the mean depression score (QIDS16) for the week prior to the pre-treatment scan was 16.9 ± 
5.1, and for the day of the post-treatment scan, it was  
8.8 ± 6.2 (change =−8.1 ± 6, t =−5.2, p < 0.001). The mean QIDS-16 score at baseline (screening) was 18.9 ± 3, and for 5-weeks 
post-treatment, it was 10.9 ± 4.8 (change =−8 ± 5.1, t =−6.3, p < 0.001). Mean change values for those included in the BOLD analyses were 
−7.3 ± 5.3 (change from scan 1 to scan 2) and −8.2 ± 5.2 (change from baseline to 5 weeks post-treatment). Both contrasts were highly 
significant (t =−5.2 and −6.2, p < 0.001). Six of the 15 (BOLD) and 16 (ASL) patients met criteria for treatment response (≤50% reductions 
in QIDS-16 score) at 5 weeks. Of the full 19 patients, all showed some decrease in depressive symptoms at 1 week, with 12 meeting criteria 
for response (change =−10.2 ± 5.3, t =−6.4, p < 0.001). All but one patient showed some decrease in QIDS-16 score at week 5 (with one 
showing no change) and 47% met criteria for response (change =−9.2 ± 5.6, t =−6.7, p < 0.001).  
Whole-brain CBF was calculated pre and post treatment and contrasted (Fig. 1). Only decreases in CBF were observed post treatment 
(vs pre), and these reached statistical significance in the left Heschl’s gyrus, left precentral gyrus, left planum temporale, left superior 
temporal gyrus, left amygdala, right supramarginal gyrus and right parietal operculum (Table S1). Based on previous findings of increased 
amygdala blood flow and metabolism in depression
24
, reductions in amygdala CBF were compared with the reductions in depressive 
symptoms between scan 1 and 2 (i.e. decreased depressed mood at the time of scanning), and a significant relationship was found (r = 0.59; 
p = 0.01). After splitting the sample into responders and non-responders at 5-weeks post-treatment, and then comparing CBF changes in a 
t-test, no significant difference was found (t = 0.11; p = 0.46).  
Next, seed-based RSFC analyses were performed using the BOLD data. Based on previous data implicating their involvement in the 
pathophysiology of depression and response to treatments
24–26
, four regions of interest (ROIs) were chosen: 1) the subgenual anterior 
cingulate cortex (sgACC), 2) the ventromedial prefrontal cortex (vmPFC), 3) the bilateral amygdala, and 4) the bilateral parahippocampus 
(PH) (Figs 2–4 and SI Appendix, Table S1).  
Increased sgACC RSFC was observed with the posterior cingulate cortex/precuneous (PCC) post-treatment (Fig. 2) but this effect did 
not correlate with reductions in depressive symptoms between scan 1 and 2 (r =−0.2; p = 0.24) and nor did it predict treatment response at 5 
weeks (t =−1.3; p = 0.11).  
Increased vmPFC RSFC was observed with the bilateral inferior-lateral parietal cortex (ilPC) post-treatment. This effect did not correlate 
with reductions in depressive symptoms between scan 1 and 2 (r =−0.26; p = 0.17) but did predict treatment response at 5 weeks, with 
responders showing significantly greater vmPFC-ilPC RSFC increases than non-responders (t = 2.1; p = 0.03).  
Decreased PH RSFC was observed with a PFC cluster incorporating the lateral and medial prefrontal cortex. This effect did not correlate 
with reductions in depressive symptoms between scan 1 and 2 (r = 0.08; p = 0.38) but did relate to treatment response at 5 weeks, with 
responders showing significantly greater PH-PFC RSFC decreases than non-responders (t =−1.9, p = 0.04). Amygdala RSFC was not 
significantly altered post treatment.  
Analyses of within network RSFC using 12 previously identified canonical RSNs
14
 revealed increased default-mode network (DMN) (t = 
2.7, p = 0.018), dorsal attention network (DAN) (t = 2.2, p = 0.042), and posterior opercular network (POP) (t = 2.7, p = 0.016) RSFC 
post-treatment; however, these changes failed to survive Bonferonni correction for multiple comparisons (revised α= 0.05/11 = 0.0042) and 
did not correlate with depression outcomes, e.g. the relationship between change in DMN RSFC and reduced QIDS-16 scores between scan 
1 and 2 were non-significant (r = 0.25; p = 0.18) and neither were changes in DMN RSFC predictive of outcomes at 5 weeks (t = 0.58; p = 
0.28). Analyses of between network RSFC using the same 12 RSNs, revealed decreased RSFC between the DMN and right frontoparietal 
network (rFP) (t =−3.6, p = 0.0031) and increased RSFC between the sensorimotor network (SM) and rFP (t = 2.2, p = 0.045) (Fig. 5); 
however, these effects did not Figure 1. Whole-brain cerebral blood flow maps for baseline versus one-day post-treatment, plus the 
difference map (cluster-corrected, p < 0.05, n = 16). Correlation chart shows post-Treatment changes in bilateral amygdala CBF versus 
changes in depressive symptoms (r = 0.59, p = 0.01). One patient failed to completed the scan 2 QIDS-16 rating, reducing the sample size to 
n = 15 for the correlation analysis. In all of the images, the left of the brain is shown on the left.  
survive FDR correction for 
multiple comparisons and did 
not relate to reduced QID-16 
scores between scan 1 and 2, 
nor response at 5 weeks.  
Lastly, based on 
indications from previous 
work
4,5,10
 we explored the 
possibility that the quality of 
the acute ‘psychedelic’ 
experience may have 
mediated the post-acute brain 
changes. We focused on a 
rating scale factor related to 
‘peak’ or ‘mystical’ experience 
and used scores for the 
high-dose psilocybin session 
as a covariate in a PH RSFC 
analysis. The PH was 
specifically chosen due to 
previous work implicating its 
involvement in related 
states
14
. Results revealed that 
patients scoring highest on 
‘peak’ or ‘mystical’ experience 
had the greatest decreases 
Figure 2. Top two rows = 
sgACC (purple) RSFC before 
and after Treatment (hot 
colours = regions of 
significantly positive 
coupling). Bottom row reveals 
regions where there was a 
significant increase in sgACC 
RSFC post-treatment (hot 
colours). All maps are 
cluster-corrected, p < 0.05, Z 
> 2.3.  
in PH RSFC in limbic (e.g. 
bilateral amygdala) and 
DMN-related cortical regions 
(e.g. the PCC). See the supplementary file for the relevant maps and discussion.  
Discussion   
The present study goes some way to addressing an important knowledge gap concerning the post-acute brain effects of serotonergic 
psychedelics. Its findings suggest that changes in brain activity observed just one-day after a high dose psychedelic experience are very 
different to those found during the acute psychedelic state. Specifically, whereas the acute psychedelic state in healthy volunteers is 
characterised by modular disintegration
14,15,27
 and global integration
14,19,28
, there are trends towards modular (re)integration and minimal 
effects on global integration/segregation post psilocybin for depression. Relating the blood flow findings to what has been seen previously in 
the acute psychedelic state is somewhat more complicated due to inconsistencies in this literature – likely due to analysis approaches and
Ĳ
 
interpretation
14,15,29
: Here we saw decreased CBF bilaterally in the temporal lobes,  
Ü 
including the left amygdala one-day post treatment. Decreased absolute CBF in subcortical and high-level association cortices have been 
previously reported with intravenous (I.V.)
15
 and now oral psilocybin
29
 but increased CBF and metabolism have also been reported with I.V. 
LSD
14
, oral psilocybin
30
, and oral ayahuasca
31
.  
Much recent research has focused on the involvement of the default-mode network in psychiatric disorders
32
, and particularly 
 
 
depression
33,34
. We previously observed decreased DMN functional integrity under psilocybin
15
 and LSD
14
, and others have with ayahuasca
27
. 
Here however, increased DMN integrity was observed one-day post treatment with psilocybin, both via seed (i.e. vmPFC and sgACC) and 
network-based approaches. Previous work has suggested that increased DMN integrity may be a marker of depressed mood and specifically, 
depressive rumination
33,35
. On this basis, increased DMN integrity post psilocybin may be surprising. The post-treatment increases in 
within-DMN RSFC and sgACC-PCC RSFC did not relate to symptom improvements but vmPFC-ilPC RSFC did (see Fig. 3). This apparent 
divergence from previous findings
35,36
 is intriguing, and deserves further discussion (below).  
It should be noted that findings of elevated within-DMN RSFC in depression are not entirely consistent in the literature
37–40
. For 
example, using a DMN-focused analysis, precuneus-DMN RSFC
38
 was found to be lower in patients than in healthy controls, and 
normalised after treatment with electroconvulsive therapy (ECT) - but only in responders
38
 – consistent with the present findings. Lower 
precuneus-DMN RSFC in depression was also seen in a separate study and the degree of this abnormality correlated with autobiographical 
memory deficits
39
. In another study, lower PCC-dmPFC and PCC-ilPC RSFC were seen in first-episode depressed patients relative to 
healthy controls
40
. In the present study, we saw increased within-DMN RSFC post treatment with psilocybin, and increased vmPFC-bilateral 
ilPC RSFC was predictive of treatment response at 5 weeks (Fig. 3). These findings Figure 3. Top two rows = vmPFC (purple) RSFC before 
and after Treatment (hot colours = regions of significantly positive coupling). Bottom row reveals regions where there was a significant 
increase in vmPFC RSFC post-treatment (hot colours). All maps are cluster-corrected, p < 0.05, Z > 2.3. Increased coupling between the 
vmPFC and the displayed regions (bottom row) was predictive of clinical response at 5-weeks posttreatment. Chart shows mean values and 
positive standard errors.  
suggest a commonality in the 
antidepressant action of ECT 
and psilocybin
38
 in which 
DMN integrity is decreased 
acutely (at least by the 
latter
14,15,27
) and increased (or 
normalised) post-acutely, 
accompanied by 
improvements in mood. This 
process might be likened to a 
‘reset’ mechanism in which 
acute modular disintegration 
(e.g. in the DMN) enables a 
subsequent re-integration and 
resumption of normal 
functioning.  
Recent meta-analyses of 
studies of resting-state CBF in 
depression have yielded 
relatively mixed results
33,41
, 
although findings of increased 
thalamic
33,41
 and sgACC 
metabolism are relatively 
consistent
33
. Here, we did not 
find any post-treatment 
changes in thalamic or sgACC 
CBF with psilocybin, either in 
whole-brain or ROI-based 
analyses. We did observe 
decreased CBF bilaterally in 
the temporal cortex however, 
including the left medial tem-
poral lobe and specifically, the 
left amygdala. Given previous 
findings of elevated 
resting-state amygdala CBF 
and Figure 4. Top two rows = 
Bilateral PH (purple) RSFC 
before and after Treatment 
(hot colours = regions of 
significantly positive coupling). Bottom row reveals regions where there was a significant decrease in PH RSFC post-treatment (cold 
colours). All maps are cluster-corrected, p < 0.05, Z > 2.3. Decreased coupling between the PH and the displayed regions (bottom row) was 
predictive of clinical response at 5-weeks post-treatment (t =−1.9, p = 0.04). Chart shows mean values and negative standard errors.  
 
metabolism in mood 
disorders
24,42,43
, the reduction in 
amygdala CBF observed here, 
and its relation to symptom 
severity, could be viewed as a 
possible remediation effect. 
Moreover, generalised 
decreases in CBF are (again) 
consistent with what has been 
previously reported with 
ECT
44
, i.e. most studies have 
documented an increase in 
CBF in the acute ‘ictal’ state, 
including in the amygdala
44
; 
however, the post-ictal period 
is characterised by decreased 
CBF, and often in those 
regions that were most 
perfused during seizure
44
. 
Acutely increased CBF has 
previously been reported with 
ayahuasca
31
 and LSD
15
 and 
increased glucose metabolism 
has been observed in the acute 
state with oral
30
 but not I.V. 
psilocybin
15
. Thus, a 
post-acute reversal of acute 
increases in CBF could be 
seen as consistent with the 
post-treatment ‘reset’ 
mechanism proposed above – 
although recent work has laid 
into Figure 5. Differences in 
between-RSN RSFC or RSN 
‘segregation’ before and after 
therapy. Each square in the 
matrix represents the strength 
of functional connectivity 
(positive = red, negative = 
blue) between a pair of 
different RSNs (beta values). 
The matrix on the far right 
displays the between-condition differences in covariance (t values). The RSNs are: 1) medial visual network, 2) lateral visual network, 3) 
occipital pole network, 4) auditory network, 5) sensorimotor network, 6) DMN, 7) parietal cortex network, 8) the dorsal attention network, 
9) the salience network, 10) posterior opercular network, 11) left frontoparietal network, 12) right frontoparietal network. White asterisks 
represent significant differences (P < 0.05, non-corrected). Both of the significant differences did not survive FDR correction for multiple 
comparisons.  
 
question whether oral psilocybin does indeed cause increases in brain CBF
29
. It would be challenging (but not impossible) to carry out acute 
and post-acute imaging in future trials of psilocybin for depression, and this may be necessary if the ‘reset’ model is to be properly tested. In 
such a study, we would advise focusing on BOLD RSFC (and perhaps simultaneous EEG-related measures) rather than CBF, due to RSFC 
and EEG offering more reliable indices of brain activity and function - plus complications regarding interpreting CBF results. The inclusion 
of a healthy control group, exposed to a consistent treatment procedure, would further strengthen the design of such a study, as would the 
inclusion of a placebo and/or active comparator arm.  
The present study’s other major positive finding was a decrease in RSFC between the bilateral parahippocampus and the PFC, an effect 
that (like increased vmPFC-ilPC RSFC) was predictive of treatment response at 5 weeks. Curiously, a post-hoc exploratory analysis 
suggested that acute ‘peak’ or ‘mystical-type’ experiences under psilocybin may mediate post-acute changes in parahippocampal RSFC 
(including decreased PH-PCC RSFC). Focusing on parahippocampal-PFC RSFC, this has generally been found to be elevated in 
depression
45
, and consistently so across the duration of a resting-state scan
46
. Prefrontal-limbic circuitry has been linked with top-down 
suppression of affective responsiveness
47
 and lower resting-state amygdala-vmPFC RSFC in combination with amygdala hyperfusion was 
found to relate to state-anxiety in healthy individuals
42
, corroborating separate findings
48
. Seven days of citalopram has been found to reduce 
amygdala-vmPFC
49 
and dorso-medial PFC-left hippocampal RSFC
50
 in healthy volunteers, somewhat consistent with the present findings.  
In conclusion, here we document for the first time, changes in resting-state brain blood flow and functional connectivity post-treatment 
with psilocybin for treatment-resistant depression. Decreased blood flow was observed which correlated (in the amygdala) with reductions 
in depressive mood. Increased within-DMN RSFC was observed post-treatment, using both seed and network-based analyses, and specific 
increases in RSFC between the vmPFC and bilateral ilPC nodes of the DMN were greatest in individuals who maintained 
treatment-response at 5 weeks. Finally, decreased PH-PFC RSFC was observed post-treatment and this was also predictive of 
treatment-response at 5 weeks. An exploratory post-hoc analysis revealed that acute ‘peak’ or ‘mystical’ experience during the high-dose 
psilocybin session correlated with changes in PH RSFC.  
This study is limited by its small sample size and absence of a control condition. Moreover, correction for multiple testing was applied to 
the full RSN but not the specific ROI based analyses. Future research with more rigorous controls and correction should serve to challenge 
and develop the present study’s findings and inferences. Assessing the relative contributions of, and potential interactions between, the 
different treatment factors (e.g. the drug and the accompanying psychological support) may be a particularly informative next step.  
Method   
This study was approved by the National Research Ethics Service (NRES) committee London – West London and was conducted in 
accordance with the revised declaration of Helsinki (2000), the International Committee on Harmonisation Good Clinical Practice (GCP) 
guidelines and National Health Service (NHS) Research Governance Framework. Imperial College London sponsored the research which 
was conducted under a Home Office license for research with schedule 1 drugs. The Medicines and Healthcare products Regulatory Agency 
(MHRA) approved the study. All patients gave written informed consent, consistent with GCP.  
Imaging  vs  clinical outcomes.  To explore relationships between significant imaging outcomes and the main clinical outcomes, we 
chose to focus on changes in depressive symptoms from: 1) pre-Treatment to scan 2 (i.e. one-day post-treatment), and 2) pre-Treatment to 
5 weeks post-Treatment. The primary clinical outcome measure, the 16-item Quick Inventory of Depressive Symptoms (QIDS-16) was 
chosen for this purpose. Relationships between imaging outcomes and contemporaneous decreases in depressive symptoms were calculated 
using a standard Pearson’s r, and relationships with the longer-term (i.e. at 5 weeks post-treatment) changes in depressive symptoms were 
calculated by splitting the sample into responders (>50% reduction in QIDS-16 scores) and non-responders at this time-point, and then 
performing a one-tailed t-test on the relevant imaging outcomes (one-tailed as directionality was unequivocally implied by the direction of 
the significant imaging outcome). We used a revised version of the QIDS-16 for 24-hour measurement for the post-treatment scan in order 
to get a contemporaneous, state-related index of depressive symptoms at this time-point.  
 
Anatomical  Scans.  Imaging was performed on a 3 T Siemens Tim Trio using a 12-channel head coil at Imanova, London, UK. 
Anatomical images were acquired using the ADNI-GO (Alzheimer’s Disease Neuroimaging Initiative, Grand Opportunity
51
) recommended 
MPRAGE parameters (1 mm isotropic voxels, TR = 2300 ms, TE = 2.98 ms, 160 sagittal slices, 256 × 256 in-plane FOV, flip angle = 9 
degrees, bandwidth = 240 Hz/pixel, GRAPPA acceleration = 2).  
BOLD  fMRI Resting State Acquisition. T2*-weighted echo-planar images (EPI) were acquired for the functional scan using 3 mm 
isotropic voxels, TR = 2000 ms, TE = 31 ms, 36 axial slices, 192 mm in-plane FOV, flip angle = 80 degree, bandwidth = 2298 Hz/pixel, 
GRAPPA acceleration = 2, number of volumes = 240, 8 min.  
BOLD Pre‐processing. Four different but complementary imaging software packages were used to analyse the fMRI data. Specifically, 
FMRIB Software Library (FSL)
52
, AFNI
53
, Freesurfer
54 
and Advanced Normalization Tools (ANTS)
55
 were used. Fifteen subjects were used for 
this analysis: one subject was discarded from the analysis due to an injury in parietal cortex and three subjects were discarded due to high 
levels of head movement. Principally, motion was measured using frame-wise displacement (FD)
56
. The criterion for exclusion was subjects 
with >20% scrubbed volumes with a scrubbing threshold of FD = 0.5. For the 15 subjects that were used in the analysis, there was no 
significant difference in the mean FD (meanFDbefore = 0.179 ± 0.088, mean-FDafter = 0.158 ± 0.084, p = 0.23). The mean percentage of 
scrubbed volumes for before and after treatment was  
4.6 ± 5% and 3.5 ± 5.2%, respectively (p = 0.56). The maximum of scrubbed volumes for before and after treatment was 17.3% and 17.7%, 
respectively. The following pre-processing stages were performed: 1) removal of the first three volumes; 2) de-spiking (3dDespike, AFNI); 
3) slice time correction (3dTshift, AFNI); 4) motion correction (3dvolreg, AFNI) by registering each volume to the volume most similar, in 
the least squares sense, to all others (in-house code); 5) brain extraction (BET, FSL); 6) rigid body registration to anatomical scans (BBR, 
FSL); 7) non-linear registration to 2 mm MNI brain (Symmetric Normalization (SyN), ANTS); 8) scrubbing
57
 - using an FD threshold of 0.5, 
scrubbed volumes were replaced with the mean of the surrounding volumes. 9) spatial smoothing (FWHM) of 6 mm (3dBlurInMask, 
AFNI); 10) band-pass filtering between 0.01 to 0.08 Hz (3dFourier, AFNI); 11) linear and quadratic de-trending (3dDetrend, AFNI); 12) 
regressing out 9 nuisance regressors (all nuisance regressors were band-pass filtered with the same band-pass filter as above): out of these, 6 
were motion-related (3 translations, 3 rotations) and 3 were anatomically-related (not smoothed). Specifically, the anatomical nuisance 
regressors were: 1) ventricles (Freesurfer, eroded in 2 mm space), 2) draining veins (DV) (FSL’s CSF minus Freesurfer’s Ventricles, eroded 
in 1 mm space) and 3) local white matter (WM) (FSL’s WM minus Freesurfer’s subcortical grey matter (GM) structures, eroded in 2 mm 
space). Regarding local WM regression, AFNI’s 3dLocalstat was used to calculate the mean local WM time-series for each voxel, using a 25 
mm radius sphere centred on each voxel
58
.  
Seed‐based RSFC. Based on prior hypotheses, 4 seeds were chosen for these analyses: 1) the bilateral PH, vmPFC, sgACC and bilateral 
amygdala. The PH seed was constructed by combining the anterior and posterior parahippocampal gyrus from the Harvard-Oxford 
probabilistic atlas, which was then thresholded at 50%. The vmPFC seed was the same as one previously used by our team in analyses of the 
acute effects of LSD
59
, psilocybin
60
 and MDMA
61
. The sgACC seed was a 5 mm sphere centred at ±2 28 -5 (MNI_152 coordinates) based on
62
. 
Bilateral amygdala seed was based on Harvard-Oxford probabilistic atlas, threshold at 50%. Mean time-series were derived for these seeds 
for each RS scan. RSFC analyses were performed using FSL’s FEAT for each subject. Pre-whitening (FILM) was applied. A higher level 
analysis was performed to compare pre-treatment and post-treatment conditions using a mixed-effects GLM (FLAME 1 + 2), cluster 
corrected (z > 2.3, p < 0.05). MRIcron was used to display the results.  
Resting  State Networks  (RSN).  RSNs were derived using Independent Component Analysis (ICA) performed on data acquired 
separately as part of the Human Connectome Project (HCP)
63
. This procedure is identical to one used previously with LSD
59
. Briefly, 20 
independent components (ICs) were derived, of which the same 12 functionally meaningful RSNs were identified, namely: medial visual 
network (VisM), lateral visual network (VisL), occipital pole network (VisO), auditory network (AUD), sensorimotor network (SM), 
default-mode network (DMN), parietal cortex network (PAR), dorsal attention network (DAN), salience network (SAL), posterior 
opercular network (POP), left fronto-parietal network (lFP) and right fronto-parietal network (rFP).  
Integrity  (within‐RSN RSFC). Network integrity was calculated for each RSN for both pre-treatment and post-treatment. All 20 HCP 
ICA components were entered into FSL’s dual regression analysis
64
. The first step of the dual regression used the components as regressors 
applied to the 4D BOLD datasets for each subject, resulting in a matrix of time-series for each ICA. The second step involved regressing 
these time-series into the same 4D scan data to get a subject-specific set of spatial maps (parameter estimate (PE) images). For each subject 
and for each condition, within each of the 12 RSNs of interest (threshold = 3), the mean PE across voxels was calculated.  
This mean PE represents the integrity value. Subsequently, paired t-tests were used to calculate the difference in integrity between 
conditions for each RSN (Bonferroni corrected for 11 RSNs, with no correction for DMN as we had a prior hypothesis).  
Segregation (between‐RSN RSFC). Between-RSN RSFC was calculated in a similar manner to previous analyses involving acute LSD59 
and psilocybin
65
. Specifically, a 12 × 12 matrix was constructed representing RSFC between different RSN pairs. For each subject and for 
each condition, the time-series for the relevant pair of RSNs, was entered into a GLM, resulting in a PE value representing the strength of 
functional connectivity between them. GLM was used rather than correlation coefficients because differences between Pearson’s corre-
lations could be a result of either signal or noise differences; therefore, it is preferable to perform regression and look for pre-treatment and 
post-treatment differences on the PE
66
. The GLM was estimated twice: 1) each RSN as a dependant variable in one model, and 2) each RSN 
as an independent variable in the second model. These two PE values were then averaged together, to generate a symmetric 12 × 12 matrix 
(Fig. 4b). Three 12 × 12 matrices were created as follows: 1) the group mean PE values for pre-Treatment treatment, 2) the group mean PE 
values for post-Treatment treatment, and 3) paired t-test to compare the PE values for the two conditions, pre-Treatment and 
post-Treatment treatment (two-tailed, 5000 permutations).  
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Supplementary data table 
 
 
 
Table 1. Regions showing decreased CBF, increased sgACC RSFC, increased vmPFC RSFC and decreased PH 
RSFC post treatment. The before (pre) and after (post) treatment columns report the z value of each condition 
separately in the same point as Max. 
 
 
Supplementary analysis 
 
Inspired by a reviewers’ request, we looked for correlation between the quality of the acute experience – with a 
specific focus on the so‐called ‘mystical experience’ and changes in RSFC in a whole brain voxel based analysis. 
The index of mystical experience we used here was the Oceanic Boundlessness (OB) dimension of the 5D‐ASC   
and the parahippocampus was chosen as the primary region of interest for the RSFC analysis ‐ due to previous 
work implicating its circuitry in phenomena relevant to the ‘mystical experience’ . We found a negative 
correlation between OB and the changes in RSFC of parahippocampus with a number of regions (precuneous, 
frontal pole, insular cortex, putamen and amygdala) (cluster correction, z > 2.3, p < 0.05). The nature of this 
relationship was such that patients who scored high on OB had the greatest decreases in RSFC. Since PH‐PFC 
RSFC was decreased as a main result (fig of main paper), this finding makes some intuitive sense. We 
recommend caution in making inferences on this result however; the analysis was conceived post‐hoc nature 
and that the patients who scored lowest on OB actually had an increase in PH RSFC in the relevant regions – 
which is inconsistent with the main result reported in the manuscript, i.e. decreased PH‐PFC RSFC.   
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Statistical maps show regions where post‐treatment changes in parahippocampal RSFC correlate with ratings of Ǯoceanic boundlessnessǯ ȋOBȌ ȋz = ʹ.͵, p < Ͳ.ͲͷȌ. The correlation plot shows the distribution of values. )t can be seen that some patients actually had increased P(‐RSFC in the relevant regions – and that these had the lowest OB scores.    
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